Journal of Bone Oncology最新文献

筛选
英文 中文
The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis 局部综合治疗对非小细胞肺癌合并孤立性骨少转移治疗结果的影响
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-05-14 DOI: 10.1016/j.jbo.2025.100688
Jia-nan Jin , Zheng-bo Song , Wen-xian Wang , Yi Li , Shi-yan Wu
{"title":"The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis","authors":"Jia-nan Jin ,&nbsp;Zheng-bo Song ,&nbsp;Wen-xian Wang ,&nbsp;Yi Li ,&nbsp;Shi-yan Wu","doi":"10.1016/j.jbo.2025.100688","DOIUrl":"10.1016/j.jbo.2025.100688","url":null,"abstract":"<div><h3>Background</h3><div>The oligometastatic status of non-small lung cancer (NSCLC) has been extensively studied over the years owing to its potential significance in long-term survival. Bone is one of the most commonly affected organs in oligometastatic NSCLC. The value of comprehensive local therapy (CLT) for NSCLC with solitary skeletal oligometastasis remains to be established.</div></div><div><h3>Methods</h3><div>Data on NSCLC cases with solitary skeletal oligometastasis were collected retrospectively between August 2008 and March 2022. Kaplan–Meier and Cox regression analyses were performed to assess clinical outcomes.</div></div><div><h3>Results</h3><div>Sixty-seven patients were included in the final analysis, 23 (34.3 %) of whom received CLT. Median progression-free survival (PFS) and overall survival (OS) were 9.9 and 27.1 months for the non-CLT cohort and 18.8 and 46.0 months for the CLT cohort, respectively. In multivariate analysis, CLT emerged as an independent prognostic factor associated with improved PFS (P = 0.031), but had no significant correlation with OS (P = 0.403). Among 23 patients treated with EGFR-TKIs, the CLT group had a median PFS of 46.8 months and a median OS that was not reached, while the non-CLT group had a median PFS of 15.7 months and a median OS of 30.7 months. CLT plus EGFR-TKI significantly improved PFS versus monotherapy (P = 0.023), though OS did not differ significantly (P = 0.095).</div></div><div><h3>Conclusions</h3><div>In NSCLC patients with solitary skeletal oligometastasis, implementation of CLT appeared to positively influence PFS. The combination of EGFR-TKI and CLT was associated with prolonged PFS compared to EGFR-TKI alone, though further validation is needed to confirm its impact on long-term survival.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100688"},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single Photon Emission Computed Tomography/X-ray Computed Tomography-based radiomics analysis for diagnosis of bone metastases in patients with breast cancer
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-05-10 DOI: 10.1016/j.jbo.2025.100686
Huiyu Su , Chunwen Ma , Dongli Sun , Jianhua Jin
{"title":"Single Photon Emission Computed Tomography/X-ray Computed Tomography-based radiomics analysis for diagnosis of bone metastases in patients with breast cancer","authors":"Huiyu Su ,&nbsp;Chunwen Ma ,&nbsp;Dongli Sun ,&nbsp;Jianhua Jin","doi":"10.1016/j.jbo.2025.100686","DOIUrl":"10.1016/j.jbo.2025.100686","url":null,"abstract":"<div><h3>Purpose</h3><div>Bones are the most metastatic site for breast cancer (BC), which can cause complications such as pathologic osteolysis, seriously affecting the quality of life of patients. This study intended to investigate the efficacy of Single Photon Emission Computed Tomography/X-ray Computed Tomography (SPECT/CT) in diagnosing bone metastases in BC and to develop a model for predicting the diagnostic effectiveness.</div></div><div><h3>Methods</h3><div>In this study, we enrolled 185 patients with BC who underwent SPECT/CT scanning. The region of interest (ROI) of each SPECT/CT image was demarcated, and the radiomics features were determined from the ROIs and screened for the optimal features signature to construct the radiomics model. Based on clinical characteristics, the clinical model was developed, and the independent predictive factors were discovered through univariate and multivariate COX regression analyses. Additionally, the radiomics nomogram was created through integrating the radiomics score and independent predictive factors. Thereafter, the receiver operating characteristic (ROC) was applied to determine the diagnostic performance of various models.</div></div><div><h3>Results</h3><div>The radiomics model was constructed based on 29 optimal features. The N stage was an independent factor, and the radiomics nomogram was created through integrating the radiomics score and N stage. Among three models, the radiomics nomogram had the highest diagnostic value for BC bone metastasis (AUC: the training set: 0.956 (0.909–1.000); the validation set: 0.936 (0.866–1.000)).</div></div><div><h3>Conclusion</h3><div>Radiomics analysis based on SPECT/CT can effectively diagnose bone metastasis in BC patients, establishing a theoretical foundation for the formulation of personalized treatment options in clinical practice.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100686"},"PeriodicalIF":3.4,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting lung metastasis in high-grade Osteosarcoma: The role of CTA Signs, with a Focus on vascular wrapping and intratumoral vascular network 预测高级别骨肉瘤的肺转移:CTA征象的作用,重点是血管包裹和肿瘤内血管网络
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-05-09 DOI: 10.1016/j.jbo.2025.100687
Zhendong Luo , Tao Ai , Zhiqiang Liu , Litong He , Yanzhen Hou , Yulin Li , Ziyan Zhou , Xinping Shen
{"title":"Predicting lung metastasis in high-grade Osteosarcoma: The role of CTA Signs, with a Focus on vascular wrapping and intratumoral vascular network","authors":"Zhendong Luo ,&nbsp;Tao Ai ,&nbsp;Zhiqiang Liu ,&nbsp;Litong He ,&nbsp;Yanzhen Hou ,&nbsp;Yulin Li ,&nbsp;Ziyan Zhou ,&nbsp;Xinping Shen","doi":"10.1016/j.jbo.2025.100687","DOIUrl":"10.1016/j.jbo.2025.100687","url":null,"abstract":"<div><h3>Objective</h3><div>Osteosarcoma is a highly malignant bone tumor with a high incidence of lung metastases (LM), significantly impacting the 5-year survival rate of patients. This study aims to predict lung metastasis in osteosarcoma based on computed tomography angiography (CTA) signs.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted involving 89 consecutive patients with osteosarcoma. Clinical features and CTA signs, including age, gender, laterality, primary site, type of bone destruction, T stage, periosteal reaction, tumor length, bone marrow involved length, vascular wrapping, and intratumoral vascular network, were evaluated. Univariate and multivariate logistic regression analyses were used to identify risk factors for LM, followed by receiver operating characteristic (ROC) curve analysis.</div></div><div><h3>Results</h3><div>The vascular wrapping and intratumoral vascular network signs were more frequently observed in LM in patients with osteosarcoma (<em>P</em> &lt; 0.05). The intratumoral vascular network remained an independent risk factor in multivariable regression analysis. ROC curve analysis demonstrated that the area under the curve (AUC) of the logistic regression model was 0.804, indicating good predictive accuracy.</div></div><div><h3>Conclusion</h3><div>Preliminary findings suggest that CTA signs, particularly vascular wrapping and the intratumoral vascular network, may have potential utility in predicting lung metastasis (LM) in osteosarcoma patients. The intratumoral vascular network, in particular, was identified as an independent risk factor.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100687"},"PeriodicalIF":3.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143931395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of skeletal pain, general symptoms and patient-reported outcome measures and their value in detecting symptomatic progression – An interdisciplinary prospective study in patients with multiple myeloma 分析骨骼疼痛、一般症状和患者报告的结果测量及其在检测症状进展中的价值——多发性骨髓瘤患者的跨学科前瞻性研究
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-05-08 DOI: 10.1016/j.jbo.2025.100685
Carlotta Pietsch , Monika Engelhardt , Gabriele Ihorst , Laura Wystrach , Johannes Jung , Hagen Schmal , Andreas Frodl , Ralph Wäsch , Evangelos Terpos , Georg W. Herget
{"title":"Analysis of skeletal pain, general symptoms and patient-reported outcome measures and their value in detecting symptomatic progression – An interdisciplinary prospective study in patients with multiple myeloma","authors":"Carlotta Pietsch ,&nbsp;Monika Engelhardt ,&nbsp;Gabriele Ihorst ,&nbsp;Laura Wystrach ,&nbsp;Johannes Jung ,&nbsp;Hagen Schmal ,&nbsp;Andreas Frodl ,&nbsp;Ralph Wäsch ,&nbsp;Evangelos Terpos ,&nbsp;Georg W. Herget","doi":"10.1016/j.jbo.2025.100685","DOIUrl":"10.1016/j.jbo.2025.100685","url":null,"abstract":"<div><div>Delayed diagnosis of multiple myeloma (MM) and progressive disease (PD) can both increase the risk of skeletal complications and do affects patients’ quality of life (QoL). In this prospective study we analyzed skeletal pain, general symptoms and patient-reported outcome measures (PROMs) in patients with MM and their value in detecting symptomatic progression.</div><div>We evaluated 502 patients, 47 with initial diagnosis (ID) of MM and 455 follow-up patients. At ID, 74% reported bone pain, mostly in the spine. General symptoms, particularly fatigue, were present in 89% of the patients. 88/455 (19%) of the follow-up patients experienced PD. Of these, 65% reported skeletal pain and 81% exhibited general symptoms, with fatigue being the most common. PD was suspected and confirmed as the cause of clinical symptoms in 59/88 (67%) and not suspected in 29/88 (33%). Occurrence and character of bone pain and general symptoms differed significantly between patients with and without PD, as did QoL and health-related status. Logistic regression analysis demonstrated that bone pain at night, pain in various locations, pain of known character with occurrence in different location, pain in the chest, pelvis, and thigh as well as fatigue and weight loss were associated with an increased risk of PD.</div><div>In conclusion, bone pain and general symptoms are helpful in identifying both MM and PD. PROMs can aid in the diagnosis of PD through symptom-based patient assessment. Serologic and, especially in the case of skeletal complaints, additional radiologic diagnostics are required to confirm suspected and to detect unexpected PD.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100685"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma 磷酸酶CTDSPL2促进骨肉瘤的增殖、侵袭、转移和瑞非尼耐药
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-04-26 DOI: 10.1016/j.jbo.2025.100684
Guannan Bai , Shaobo Zhao , Manli Zhao , Limiao Chen , Wenhao Chen
{"title":"The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma","authors":"Guannan Bai ,&nbsp;Shaobo Zhao ,&nbsp;Manli Zhao ,&nbsp;Limiao Chen ,&nbsp;Wenhao Chen","doi":"10.1016/j.jbo.2025.100684","DOIUrl":"10.1016/j.jbo.2025.100684","url":null,"abstract":"<div><div>Osteosarcoma is the most common bone malignancy in children and adolescents. Patients with metastatic and recurrent osteosarcoma have poor prognosis. Regorafenib is a multi-kinase inhibitor recommended as a complement to standard chemotherapy in the treatment of advanced osteosarcoma. The mechanisms associated with regorafenib resistance remains unclear.</div><div>In this study we performed transcriptomics, proteomics and phosphorylated proteomics using regorafenib-treated osteosarcoma cell lines (MG-63, HOS-MNNG for transcriptomics, HOS-MNNG for proteomics and phosphorylated proteomics). After comprehensive multiomics and verification analyses of differentially expressed genes, essential genes for the malignancy of osteosarcoma cells were identified. The effects of essential genes on the proliferation, invasion, and migration of osteosarcoma were determined. The study also evaluated their role in the apoptosis of osteosarcoma cells. The up-regulation of essential genes was determined by immunohistochemistry assays.</div><div>Using comprehensive multiomics and verification analyses we found that the CTDSPL2 gene might play a role in the malignancy and Regorafenib resistance in osteosarcoma. In vitro and clinical specimen assays demonstrated that CTDSPL2 promotes the proliferation, invasion and metastasis of osteosarcoma cells, while inhibiting tumor cell apoptosis.</div><div>In conclusion CTDSPL2 was identified as an essential gene for survival of osteosarcoma cells. Knockdown of CTDSPL2 expression significantly inhibited the proliferation, invasion, and metastasis of osteosarcoma cells, suggesting that it is involved in the formation and development of osteosarcoma tumors. Our data showed that CTDSPL2 is a potential therapeutic target for patients with osteosarcoma.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100684"},"PeriodicalIF":3.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a nomogram for prognosis of bone metastatic disease in patients with esophageal squamous cell carcinoma: A retrospective study in the SEER database and China cohort 食管鳞状细胞癌患者骨转移疾病预后nomogram的建立和验证:SEER数据库和中国队列的回顾性研究
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-04-26 DOI: 10.1016/j.jbo.2025.100683
Bo Huang , Wei-Dong Wang , Fang-Cai Wu , Xiao-Mei Wang , Bu-Qing Shao , Ying-Miao Lin , Guo-Xing Zheng , Gui-Qiang Li , Can-Tong Liu , Yi-Wei Xu , Xin-Jia Wang
{"title":"Development and validation of a nomogram for prognosis of bone metastatic disease in patients with esophageal squamous cell carcinoma: A retrospective study in the SEER database and China cohort","authors":"Bo Huang ,&nbsp;Wei-Dong Wang ,&nbsp;Fang-Cai Wu ,&nbsp;Xiao-Mei Wang ,&nbsp;Bu-Qing Shao ,&nbsp;Ying-Miao Lin ,&nbsp;Guo-Xing Zheng ,&nbsp;Gui-Qiang Li ,&nbsp;Can-Tong Liu ,&nbsp;Yi-Wei Xu ,&nbsp;Xin-Jia Wang","doi":"10.1016/j.jbo.2025.100683","DOIUrl":"10.1016/j.jbo.2025.100683","url":null,"abstract":"<div><h3>Purpose</h3><div>Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor worldwide, and individuals with ESCC and bone metastasis (BM) often face a challenging prognosis. Our objective was to identify the risk and prognostic factors associated with BM in patients with ESCC and develop a nomogram for predicting Cancer-Specific Survival (CSS) which following the occurrence of BM.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of data pertaining to ESCC patients with BM registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015, as well as those treated at a Chinese institution from 2006 to 2020. Significant prognostic factors for CSS were assessed through univariate and multivariate Cox regression analyses. Subsequently, a nomogram was developed utilizing the SEER database and externally validated using real-world evidence from a Chinese cohort.</div></div><div><h3>Results</h3><div>A total of 266 patients from the SEER database and 168 patients from the Chinese cohort were included in the analysis. In the SEER cohort, multivariate analysis indicated that chemotherapy, radiotherapy, liver metastasis, brain metastasis, and sex were independent prognostic factors for ESCC with BM. The prognostic nomogram demonstrated areas under the ROC curve (AUCs) of 0.823, 0.796, and 0.800, respectively, for predicting 3-, 6-, and 12-month CSS. In the Chinese validation cohort, the nomogram exhibited acceptable discrimination (AUCs: 0.822, 0.763, and 0.727) and calibration ability.</div></div><div><h3>Conclusion</h3><div>The study developed a prognostic nomogram to predict CSS in ESCC patients with BM, which can help clinicians assess survival and make individualized treatment decisions.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100683"},"PeriodicalIF":3.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies 骨转移中的人工智能:92项研究指南依从性的系统回顾
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-04-24 DOI: 10.1016/j.jbo.2025.100682
Lotte R. van der Linden , Ioannis Vavliakis , Tom M. de Groot , Paul C. Jutte , Job N. Doornberg , Santiago A. Lozano-Calderon , Olivier Q. Groot
{"title":"Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies","authors":"Lotte R. van der Linden ,&nbsp;Ioannis Vavliakis ,&nbsp;Tom M. de Groot ,&nbsp;Paul C. Jutte ,&nbsp;Job N. Doornberg ,&nbsp;Santiago A. Lozano-Calderon ,&nbsp;Olivier Q. Groot","doi":"10.1016/j.jbo.2025.100682","DOIUrl":"10.1016/j.jbo.2025.100682","url":null,"abstract":"<div><h3>Background</h3><div>The last decade has witnessed a surge in artificial intelligence (AI). With bone metastases becoming more prevalent, there is an increasing call for personalized treatment options, a domain where AI can greatly contribute. However, integrating AI into clinical settings has proven to be difficult. Therefore, we aimed to provide an overview of AI modalities for treating bone metastases and recommend implementation-worthy models based on TRIPOD, CLAIM, and UPM scores.</div></div><div><h3>Methods</h3><div>This systematic review included 92 studies on AI models in bone metastases between 2008 and 2024. Using three assessment tools we provided a reliable foundation for recommending AI modalities fit for clinical use (TRIPOD or CLAIM ≥ 70 % and UPM score ≥ 10).</div></div><div><h3>Results</h3><div>Most models focused on survival prediction (44/92;48%), followed by imaging studies (37/92;40%). Median TRIPOD completeness was 70% (IQR 64–81%), CLAIM completeness was 57% (IQR 48–67%), and UPM score was 7 (IQR 5–9). In total, 10% (9/92) AI modalities were deemed fit for clinical use.</div></div><div><h3>Conclusion</h3><div>Transparent reporting, utilizing the aforementioned three evaluation tools, is essential for effectively integrating AI models into clinical practice, as currently, only 10% of AI models for bone metastases are deemed fit for clinical use. Such transparency ensures that both patients and clinicians can benefit from clinically useful AI models, potentially enhancing AI-driven personalized cancer treatment.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100682"},"PeriodicalIF":3.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting lung cancer bone metastasis using CT and pathological imaging with a Swin Transformer model 基于Swin Transformer模型的CT及病理影像预测肺癌骨转移
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-04-17 DOI: 10.1016/j.jbo.2025.100681
Wanling Li , Xin Zou , Jie Zhang , Minghong Hu , Guanfeng Chen , Shanshan Su
{"title":"Predicting lung cancer bone metastasis using CT and pathological imaging with a Swin Transformer model","authors":"Wanling Li ,&nbsp;Xin Zou ,&nbsp;Jie Zhang ,&nbsp;Minghong Hu ,&nbsp;Guanfeng Chen ,&nbsp;Shanshan Su","doi":"10.1016/j.jbo.2025.100681","DOIUrl":"10.1016/j.jbo.2025.100681","url":null,"abstract":"<div><div>Bone metastasis is a common and serious complication in lung cancer patients, leading to severe pain, pathological fractures, and reduced quality of life. Early prediction of bone metastasis can enable timely interventions and improve patient outcomes. In this study, we developed a multimodal Swin Transformer-based deep learning model for predicting bone metastasis risk in lung cancer patients by integrating CT imaging and pathological data. A total of 215 patients with confirmed lung cancer diagnoses, including those with and without bone metastasis, were included. The model was designed to process high-resolution CT images and digitized histopathological images, with the features extracted independently by two Swin Transformer networks. These features were then fused using decision-level fusion techniques to improve classification accuracy. The Swin-Dual Fusion Model achieved superior performance compared to single-modality models and conventional architectures such as ResNet50, with an AUC of 0.966 on the test data and 0.967 on the training data. This integrated model demonstrated high accuracy, sensitivity, and specificity, making it a promising tool for clinical application in predicting bone metastasis risk. The study emphasizes the potential of transformer-based models to revolutionize bone oncology through advanced multimodal analysis and early prediction of metastasis, ultimately improving patient care and treatment outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100681"},"PeriodicalIF":3.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of preoperative hematocrit and platelet count with morbidity after pathologic fracture fixation 术前红细胞压积和血小板计数与病理性骨折固定后发病率的关系
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-04-05 DOI: 10.1016/j.jbo.2025.100679
Mohyeddine El Sayed , Ryley Zastrow , Sassine Youssef , Adam S. Levin
{"title":"Associations of preoperative hematocrit and platelet count with morbidity after pathologic fracture fixation","authors":"Mohyeddine El Sayed ,&nbsp;Ryley Zastrow ,&nbsp;Sassine Youssef ,&nbsp;Adam S. Levin","doi":"10.1016/j.jbo.2025.100679","DOIUrl":"10.1016/j.jbo.2025.100679","url":null,"abstract":"<div><h3>Background</h3><div>Anemia and abnormal platelet count are common among patients with cancer and are associated with complications after orthopaedic procedures. We studied associations between these conditions and morbidity within 30 days after surgery for pathologic femur or humerus fracture.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed data from the National Surgery Quality Improvement Project database for 145,030 adults following surgical fixation of a pathologic femur or humerus fracture from 2010 to 2020. Multivariable logistic regressions compared 30-day complications between patients with mild or severe anemia versus those with normal hematocrit and between patients with thrombocytopenia or thrombocytosis versus those with normal platelet count.</div></div><div><h3>Results</h3><div>Likelihood of extended hospitalization (≥6 days) was higher in patients with mild anemia (odds ratio [OR]: 1.47; 95 % confidence interval [CI]: 1.44, 1.51) and severe anemia (OR: 2.14; 95 % CI: 2.06, 2.23). Likelihood of all-cause morbidity was also higher among those with mild anemia (OR: 1.17; 95 % CI: 1.13, 1.21) and severe anemia (OR: 1.35; 95 % CI: 1.28, 1.42). Similarly, likelihood of extended hospitalization was higher in patients with thrombocytopenia (OR: 1.25; 95 % CI: 1.22, 1.29) and thrombocytosis (OR: 1.24; 95 % CI: 1.13, 1.36). Likelihood of all-cause morbidity was also higher for those with thrombocytopenia (OR: 1.12; 95 % CI: 1.07, 1.16) and thrombocytosis (OR: 1.21; 95 % CI: 1.07, 1.37).</div></div><div><h3>Conclusion</h3><div>Preoperative anemia and platelet abnormalities were potentially modifiable risk factors associated with postoperative complications following surgery for pathologic fracture.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100679"},"PeriodicalIF":3.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of myeloma bone disease: When, how often, and for how long? 骨髓瘤骨病的治疗:何时、多久、持续多久?
IF 3.4 2区 医学
Journal of Bone Oncology Pub Date : 2025-04-01 DOI: 10.1016/j.jbo.2025.100680
Michael Tveden Gundesen , Fredrik Schjesvold , Thomas Lund
{"title":"Treatment of myeloma bone disease: When, how often, and for how long?","authors":"Michael Tveden Gundesen ,&nbsp;Fredrik Schjesvold ,&nbsp;Thomas Lund","doi":"10.1016/j.jbo.2025.100680","DOIUrl":"10.1016/j.jbo.2025.100680","url":null,"abstract":"<div><div>The landscape of MM has changed dramatically in recent years. Several new and more effective treatments have been introduced that not only makes patients live longer but also brings them into a deeper remission. This makes the potential total exposure of bone protective treatment much higher but perhaps also less needed. New and more precise imagining techniques have been introduced making detection of bone disease more sensitive, and the introduction of SLiM-CRAB criteria have changed the parameters used in old clinical trials investigating treatment of MM bone disease. New data have also emerged investigating the effect of the RANKL inhibitor denosumab compared to zoledronic acid (ZOL). Randomized trials have investigated longer treatment durations, which becomes more relevant as patients now live longer.</div><div>In addition in this review, data regarding interval between individual treatment, impact of remission status, new data in relation to rebound after discontinuation and of denosumab, as well as the rational for drug holidays before dental procedures will also be discussed.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100680"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信